EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, PVCT: Provectus Biopharmaceuticals Inc

18 Nov 2025
LAST:

0.0692

CHANGE:
 0.01		OPEN:
0.0649		HIGH:
0.0695		ASK:
0.0000		VOLUME:
123.4K
CHG(%):
13.44		PREV:
0.0610		LOW:
0.0649		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
18 Nov 250.06490.06950.06490.0692123.4K
17 Nov 250.06490.06490.06050.0610156.9K
14 Nov 250.06190.06490.06020.064997.3K
13 Nov 250.06000.06490.05990.0645213.6K
12 Nov 250.06450.06450.05910.063548.1K
11 Nov 250.06490.06490.05530.0602114.5K
10 Nov 250.06450.06450.05500.0584520.6K
07 Nov 250.06370.06400.05680.0640483.1K
06 Nov 250.06990.06990.06010.06401.01M
05 Nov 250.07200.07200.06500.0696349.7K

PROFILE

Name:Provectus Biopharmaceuticals Inc
About:Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines for various diseases in the United States. The company's lead molecule is rose bengal sodium, a member of a class of molecules called halogenated xanthenes. Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers and blood cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. The company is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, it develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It also has collaboration agreement with Bascom Palmer Eye Institute, and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.
Sector:Healthcare
Industry:Biotechnology
Address:800 South Gay Street, Knoxville, TN, United States, 37929
Website:https://www.provectusbio.com
CUSIP:74373F100
CIK:0000315545
ISIN:US74373P1084
FIGI:BBG000PGQWR8
LEI:549300PIIESQMJOOJG14

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.067.1%
MA10:0.068.3%
MA20:0.072.4%
MA50:0.074.8%
MA100:0.0810.3%
MA200:0.0822.3%
STO9:93.91 
STO14:72.48
RSI14:45.06
WPR14:-20.59
MTM14:0.00
ROC14:-0.01 
ATR:0.01 
Week High:0.070.4%
Week Low:0.0625.1%
Month High:0.0812.7%
Month Low:0.0622.3%
Year High:0.15119.2%
Year Low:0.0625.8%
Volatility:17.56